Ignite Creation Date:
2024-05-06 @ 1:19 PM
Last Modification Date:
2024-10-26 @ 1:12 PM
Study NCT ID:
NCT03994575
Status:
COMPLETED
Last Update Posted:
2021-07-27
First Post:
2019-06-20
Brief Title:
North American Acute Coronary Syndrome ACS Reflective III Pilot
Sponsor:
Canadian Heart Research Centre
Organization:
Canadian Heart Research Centre
Study Overview
Official Title:
North American Acute Coronary Syndrome ACS Reflective III Pilot
Status:
COMPLETED
Status Verified Date:
2021-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The North American ACS Reflective III Pilot is an observational Quality Enhancement Research Initiative QuERI knowledge translation program designed to give feedback to physicians on their post-ACS lipid-lowering management in an effort to support their decision-making and choice of therapies and thereby better achieve evidence-based guideline-recommended management of post-ACS patients The ACS Reflective III Pilot follows the completed ACS Registries I II and III ACS Reflective I and the ongoing ACS Reflective II programs
Detailed Description:
The main objectives are
1 To identify and describe post-ACS patients who do not achieve guideline-recommended LDL-C target 18 mmolL in Canada 50 LDL-C lowering on high-intensity statin in the US
2 To identify opportunities where PCSK9 inhibitor therapy may be of potential benefit in the management of post-ACS patients to achieve guideline-recommended LDL-C goal by 1 year follow-up and
3 To determine reasons why physicians are not prescribing guideline-recommended LDL-C lowering therapies andor patients are not achieving guideline-recommended LDL-C goals
1 To identify and describe post-ACS patients who do not achieve guideline-recommended LDL-C target 18 mmolL in Canada 50 LDL-C lowering on high-intensity statin in the US
2 To identify opportunities where PCSK9 inhibitor therapy may be of potential benefit in the management of post-ACS patients to achieve guideline-recommended LDL-C goal by 1 year follow-up and
3 To determine reasons why physicians are not prescribing guideline-recommended LDL-C lowering therapies andor patients are not achieving guideline-recommended LDL-C goals
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None